8-K: Allurion Technologies Prices $20 Million Public Offering and Concurrent Private Placement

Allurion Technologies has announced the pricing of a $20 million public offering and concurrent private placement to fund clinical trials, commercial sales, and research and development.

Summary

• Allurion Technologies has priced a public offering of 14,406,508 shares of common stock and warrants at $1.20 per share, aiming to raise $17.3 million before expenses.
• The company has also granted underwriters a 30-day option to purchase an additional 15% of the securities offered.
• Concurrently, Allurion will sell a new series of preferred stock and private placement warrants to RTW Investments for approximately $2.7 million.
• The total gross proceeds from both the public offering and private placement are expected to be around $20 million.
• The company plans to use the net proceeds to fund clinical trials, commercial sales, research and development, working capital, and general corporate purposes.
• The public offering and private placement are expected to close on or about July 1, 2024, subject to customary closing conditions.

Sentiment

Score: 7

Explanation: The document is generally positive, indicating a successful capital raise. However, the low offering price and reliance on a private placement suggest some underlying challenges. The company is taking steps to secure its financial future, which is a positive sign.

Positives

• The capital raise will provide funds for clinical trials, commercial sales, and research and development.
• The concurrent private placement with RTW Investments demonstrates investor confidence.
• The company has secured an option for underwriters to purchase additional securities, potentially increasing the total capital raised.

Negatives

• The offering price of $1.20 per share may be seen as dilutive to existing shareholders.
• The company is relying on a concurrent private placement to reach its $20 million target, which may introduce execution risk.

Risks

• The closing of the public offering and private placement is subject to customary closing conditions, which may not be met.
• Market conditions could impact the success of the offering and the company's ability to raise the full $20 million.
• The company's ability to use the proceeds effectively to achieve its goals is subject to execution risk.
• The preferred stock issued in the private placement requires stockholder approval for conversion, which may not be obtained.

Future Outlook

The company intends to use the net proceeds from the offering and private placement to fund clinical trials, commercial sales, research and development, working capital, and general corporate purposes.

Management Comments

• The company intends to use the net proceeds from the underwritten public offering and the concurrent private placement to continue to fund clinical trials, commercial sales and research and development, and for working capital and general corporate purposes.

Industry Context

This capital raise is occurring in the context of the company's efforts to commercialize its weight loss platform, including the Allurion Gastric Balloon and Virtual Care Suite. The funds will support the company's growth and expansion in the obesity treatment market.

Comparison to Industry Standards

• The offering price of $1.20 per share is relatively low, which may be indicative of the company's current valuation and need for capital.
• The use of a concurrent private placement with a strategic investor like RTW Investments is a common strategy for companies seeking to raise capital while also securing long-term support.
• The inclusion of warrants in the public offering is a typical incentive for investors in early-stage companies.
• The company's focus on clinical trials, commercial sales, and research and development is consistent with the priorities of companies in the medical device and healthcare technology sectors.

Related Party Transactions

• The company is selling a new series of preferred stock and private placement warrants to funds affiliated with RTW Investments, a significant stockholder of the Company.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's ability to fund its operations and growth will be enhanced.
• Customers may benefit from the company's continued investment in research and development.
• Employees may benefit from the company's improved financial stability.

Next Steps

• The company will proceed with the closing of the public offering and private placement, expected on or about July 1, 2024.
• The company will use the net proceeds to fund clinical trials, commercial sales, research and development, working capital, and general corporate purposes.
• The company will seek stockholder approval for the conversion of the Series A Preferred Stock and exercise of the Private Placement Warrants by December 31, 2025.

Key Dates

Keywords

public offering, private placement, common stock, warrants, preferred stock, capital raise, clinical trials, research and development, RTW Investments, Allurion Technologies